- Merck/Ridgeback Bio partnership on tablet form of antiviral molnuparivir attracts US Government interest for early-stage COVID treatment.
- Starpharma’s Viraleze for prevention and early-stage COVID treatment as a nasal spray gets traction in Europe and India.
- Monoclonal antibody-based treatments are more speculative and likely to be very expensive.
- Investment in early-stage treatments limited as Ridgeback Bio is private and Merck too big for molnuparivir to affect its share price. Opportunity with Starpharma (Viraleze and other areas) as it is unloved currently.
For further details see:
Early-Stage Covid Treatment Prospects: Merck/Ridgeback Bio And Starpharma Lead The Pack